Cytokinetics Names Nancy Wysenski to Board of Directors
Cytokinetics has appointed Nancy Wysenski to its Board of Directors, strengthening its commercial and market access expertise as the company advances its drug pipeline. Wysenski brings over 25 years of experience in biopharmaceuticals, having previously held senior roles at Vertex Pharmaceuticals and Endo Pharmaceuticals. Her expertise in commercialization and organizational leadership is expected to play a crucial role as Cytokinetics navigates regulatory processes and prepares for potential marketing authorizations for its key products, including omecamtiv mecarbil and reldesemtiv.
- Nancy Wysenski's appointment enhances Cytokinetics' leadership in commercial strategy.
- Wysenski's extensive experience could improve the company's market access and commercialization efforts.
- Concerns regarding continuity and experience gaps due to new leadership.
Appointment Strengthens Commercial, Market Access and Specialty Sales Expertise as Company Advances Pipeline Toward Potential Commercialization
SOUTH SAN FRANCISCO, Calif., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Nancy Wysenski has been appointed to the company’s Board of Directors. Ms. Wysenski brings more than 25 years of experience in the biopharmaceutical industry. Throughout her career, she has focused on commercial launch strategy, executive leadership, operational excellence and optimizing market access across many therapeutic areas including the rare disease and specialty pharmaceutical sectors.
“We are pleased to welcome Nancy to our Board,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “As a seasoned commercial and organizational leader, her track record of success in commercialization and corporate governance will be invaluable as we advance our pipeline toward marketing authorizations and navigate the evolving landscape of access for patients with high unmet needs.”
Ms. Wysenski served as the Executive Vice President and Chief Commercial Officer of Vertex Pharmaceuticals from December 2009 through her retirement in June 2012. During her tenure at Vertex, Ms. Wysenski was responsible for the launches of Incivek and Kalydeco. Prior to joining Vertex, Incorporated, Ms. Wysenski held the position of Chief Operating Officer of Endo Pharmaceuticals, Inc., a specialty pharmaceutical company, where she led sales, marketing, commercial operations, supply chain management, human resources and various business development initiatives. Prior to her role at Endo, Ms. Wysenski participated in the establishment of EMD Pharmaceuticals, Inc., where she held various leadership positions, including the role of President and Chief Executive Officer from 2001 to 2006 and Vice President of Commercial from 1999 to 2001. From 1984 to 1998, Ms. Wysenski held several sales-focused roles at major pharmaceutical companies, including Vice President of Field Sales for Astra Merck, Inc. Ms. Wysenski serves as a member of the board of directors of Provention Bio Inc., and Alkermes plc, each a publicly traded pharmaceutical company. Ms. Wysenski formerly served as a director for Tetraphase Pharmaceuticals, Dova Pharmaceuticals Inc., Reata Pharmaceuticals, Inc. and Inovio Pharmaceuticals, Inc. She is a founder of the Research Triangle Park chapter of the Healthcare Business Women's Association and served on the Nominating Committee and National Advisory Board of the Healthcare Businesswomen's Association.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is collaborating with Amgen Inc. (Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle activator. Omecamtiv mecarbil is the subject of an international clinical trials program in patients with heart failure including GALACTIC-HF, of which topline results were recently reported, and METEORIC-HF, which is ongoing. Amgen holds an exclusive worldwide license to develop and commercialize omecamtiv mecarbil with a sublicense held by Servier for commercialization in Europe and certain other countries. Cytokinetics is developing reldesemtiv, a fast skeletal muscle troponin activator (FSTA) for the potential treatment of ALS and other neuromuscular indications following conduct of FORTITUDE-ALS and other Phase 2 clinical trials. The company is considering potential advancement of reldesemtiv to Phase 3 pending ongoing regulatory interactions. Cytokinetics is collaborating with Astellas Pharma Inc. (Astellas) to research, develop and commercialize other novel mechanism skeletal sarcomere activators (not including FSTAs). Licenses held by Amgen and Astellas are subject to specified co-development and co-commercialization rights of Cytokinetics. Cytokinetics is also developing CK-274, a novel cardiac myosin inhibitor that company scientists discovered independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies. Cytokinetics has granted Ji Xing Pharmaceuticals Limited an exclusive license to develop and commercialize CK-274 in China and Taiwan, in accordance with Cytokinetics’ planned global registration programs. Cytokinetics is conducting REDWOOD-HCM, a Phase 2 clinical trial of CK-274 in patients with obstructive HCM. Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757
FAQ
Who is Nancy Wysenski and what is her background?
What is the significance of Nancy Wysenski's appointment to Cytokinetics?
What products is Cytokinetics developing?
How does Wysenski's experience impact Cytokinetics' future?
